The growing adoption rates of payment technologies by small-business owners might partially explain why credit demand for working capital from small firms remains stubbornly low, even as their balance sheets and credit-worthiness improve, according to Robb Hilson, head of Bank of America small-business segment.
Exactly how much cost drug companies can wring out of their balance sheets as patents expire is one of the key questions facing the pharmaceutical industry as they head over what analysts are calling the patent cliff.